Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.16 - $0.47 $26,324 - $77,329
-164,531 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$0.42 - $0.62 $7,872 - $11,621
18,744 Added 12.86%
164,531 $77,000
Q4 2021

Feb 10, 2022

SELL
$0.56 - $1.71 $2,282 - $6,969
-4,076 Reduced 2.72%
145,787 $83,000
Q3 2021

Nov 12, 2021

BUY
$1.21 - $1.8 $10,829 - $16,110
8,950 Added 6.35%
149,863 $249,000
Q2 2021

Aug 05, 2021

BUY
$1.56 - $1.98 $219,824 - $279,007
140,913 New
140,913 $235,000
Q2 2019

Aug 14, 2019

SELL
$0.39 - $0.7 $42,790 - $76,802
-109,718 Closed
0 $0
Q1 2019

May 01, 2019

SELL
$0.43 - $0.68 $909 - $1,438
-2,115 Reduced 1.89%
109,718 $62,000
Q4 2018

Jan 31, 2019

BUY
$0.39 - $0.7 $15,459 - $27,748
39,640 Added 54.91%
111,833 $44,000
Q3 2018

Nov 07, 2018

BUY
$0.44 - $3.02 $970 - $6,662
2,206 Added 3.15%
72,193 $37,000
Q2 2018

Aug 06, 2018

BUY
$1.66 - $3.82 $116,178 - $267,350
69,987 New
69,987 $154,000

Others Institutions Holding AMPE

# of Institutions
1
Shares Held
96.6K
Call Options Held
0
Put Options Held
0

About Ampio Pharmaceuticals, Inc.


  • Ticker AMPE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,287,008
  • Description
  • Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an...
More about AMPE
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.